araag2/HINT huggingface dataset:
Clinical trial NCT01248936 (phase 2, status: completed)
Conditions: malignant melanoma
ICD codes: C43.0, C43.31, C43.51, C43.9, C43.4, C43.52, C43.10
Drugs: ro5185426
SMILES: CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed metastatic melanoma with documented BRAF V600E mutation,
             determined by the cobas BRAF V600 mutation test

          -  Patients with either measurable or non-measurable disease

          -  Adequate recovery from most recent systemic or local treatment for metastatic melanoma

          -  Adequate organ function

          -  For women of childbearing potential, agreement to the use of two acceptable methods of
             contraception, including one barrier method, during the study and for 6 months after
             discontinuation of RO5185426

          -  For men with female partners of childbearing potential, agreement to use a latex
             condom, and to advise their female partner to use an additional method of
             contraception during the study and for 6 months after discontinuation of RO5185426

          -  Negative serum or urine pregnancy test within 7 days of commencement of treatment in
             premenopausal women. Women who are either surgically sterile or have been
             post-menopausal for at least 1 year are eligible to participate in this study

          -  Agreement not to donate blood or blood products during the study and for at least 6
             months after discontinuation of RO5185426; for male patients, agreement not to donate
             sperm during the study and for at least 6 months after discontinuation of RO5185426

        Exclusion Criteria:

          -  Pregnant or breast-feeding

          -  Concurrent anti-tumor therapy

          -  Uncontrolled medical illness

          -  History of congenital prolonged QT syndrome or patients with a mean QTc interval
             greater than 470 milliseconds at baseline, or ongoing grade 2 or greater cardiac
             arrhythmia
Clinical trial NCT00189332 (phase 2, status: completed)
Conditions: melanoma, unresectable metatstatic cutaneous melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: 852a
SMILES: CCC1=NC2=C(N1CCCCNS(C)(=O)=O)C1=CC=CC=C1N=C2N
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced melanoma not responding to 1st line chemotherapy

          -  Histological evidence of melanoma

          -  Measurable disease according to RECIST criteria

          -  ECOG performance status less than or equal to 2

          -  Life expectancy 6 months or more

          -  Normal organ and bone marrow function as defined by hematological and serum chemistry
             limits

          -  Adequate contraception for females of childbearing potential

        Exclusion Criteria:

          -  Stage IV disease which has previously progressed during interferon treatment.

          -  Restriction of some therapies/medications for a certain timeframe prior to enrollment
             and during the study including: investigational drugs, high dose corticosteroids,
             immunotherapy, immunosuppressive medications, radiotherapy and drugs known to prolong
             QT interval and/or induce Torsades De Pointes

          -  History of uncontrolled seizure disorders

          -  Uncontrolled coagulation disorders.

          -  History or evidence of myocardial ischemia, congestive heart failure or arrythmias
             requiring treatment in the past 6 months

          -  History of uncontrolled intercurrent or chronic illness

          -  Concurrent malignancies.

          -  Brain metastases.

          -  HIV positive.

          -  Prolonged QTc interval

          -  Uncontrolled intercurrent or chronic illnesses.

          -  Pregnant or lactating women
Clinical trial NCT00248040 (phase 2, status: completed)
Conditions: ischemia-reperfusion injury, kidney diseases
ICD codes: I12.9, N18.9, Q61.9, I12.0, D63.1, N18.1, N18.5
Drugs: reparixin continuous infusion, reparixin intermittent infusion
SMILES: [H][C@](C)(C(O)=NS(C)(=O)=O)C1=CC=C(CC(C)C)C=C1, [H][C@](C)(C(O)=NS(C)(=O)=O)C1=CC=C(CC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients accepted and listed for renal transplantation due to end
             stage renal disease (ESRD)

          -  Planned isolated single kidney transplant from a non-living donor with brain death

          -  Recipients of a kidney maintained in cold storage

          -  Recipients at risk of developing DGF

          -  Planned induction with steroids + mycophenolate mofetil (MMF) or mycophenolic acid +
             biological induction

          -  Patient willing and able to comply with the protocol procedures for the duration of
             the study, including scheduled follow-up visits and examinations

          -  Patient given written informed consent, prior to any study-related procedure not part
             of normal medical care, with the understanding that consent may be withdrawn by the
             patient at any time without prejudice to their future medical care

        Exclusion Criteria:

          -  Recipients of an intended multiple organ transplant

          -  Recipients of a kidney from a living donor

          -  Recipients of a kidney from a non-heart beating donor

          -  Recipients of double kidney transplant

          -  Re-transplant >2

          -  Recipients of a kidney maintained by pulsatile machine perfusion

          -  Concurrent sepsis

          -  Recipients with hepatic dysfunction at the time of transplant

          -  Clinical contraindications to central line access, or arteriovenous fistula, if any,
             not suitable for infusion of investigational product

          -  Hypersensitivity to non steroidal anti-inflammatory drugs (NSAIDs)

          -  Patients simultaneously participating in any other clinical trials involving an
             investigational drug not yet authorized for use in kidney transplant

          -  Pregnant or breast-feeding women
Clinical trial NCT01119430 (phase 2, status: terminated)
Conditions: major depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: du125530, placebo
SMILES: CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    interim analysis suggested no differences with whole sample
  
Eligibility criteria:

        Inclusion Criteria:

          -  Consecutive eligible patients aged 18 to 70

          -  Diagnosis of unipolar major depression using DSM-IV criteria with moderate to severe
             symptoms (score e 18 on the Hamilton Depression Rating Scale-HDRS- of 17 items).

          -  There was a wash-out of 1 week of any antidepressant drug (specifically 28 days for
             fluoxetine) prior entering the study.

          -  Written informed consent was obtained from all participants.

        Exclusion Criteria:

          -  Concurrent psychiatric disorders (DSM IV axis I, II cluster A or B)

          -  Failure to respond to drug treatment in current depressive episode

          -  Previous resistance to SSRIs or other antidepressant drug

          -  Suicide risk score e 3 on the HDRS.

          -  Participation in other drug trials within the previous month

          -  Presence of delusions or hallucinations

          -  History of substance abuse (including alcohol) in the past three months

          -  Pregnancy or lactation

          -  Organic brain disease or history of seizures

          -  Serious organic illnesses such as hypo or hyperthyroidism,cardiac arrhythmias, asthma,
             diabetes mellitus.

          -  Myocardial infarction in the past 6 month

          -  Frequent or severe allergic reactions

          -  Concomitant use of other psychotropic drugs (benzodiazepines were allowed), lockers or
             catecholamine-depleting agents

          -  Current structured psychotherapy.
Clinical trial NCT00306254 (phase 2, status: completed)
Conditions: venous thrombosis
ICD codes: K64.5, I67.6, O87.3, O22.50, O22.51, O22.52, O22.53
Drugs: pd 0348292, enoxaparin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Adult men or women scheduled for an elective, unilateral total knee replacement who
             are otherwise healthy.

        Exclusion Criteria:

          -  History of deep vein thrombosis or pulmonary embolism, suspected postthrombotic state,
             bleeding or clotting disorders, or cardiovascular, renal or liver disease within the
             past year
Clinical trial NCT00420511 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin, placebo, metformin
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Men and women between the ages of 30 and 75 inclusive

          2. Physician-diagnosed type 2 diabetes on 0-2 oral hypoglycemic agents

          3. Negative for anti-glutamic acid decarboxylase (anti-GAD_ antibodies (to rule out
             Latent Autoimmune Diabetes of Adults (LADA)

          4. A1c at screening between 6.5% and 9% inclusive if on no oral hypoglycemic agents or
             6.0% and 9.0% inclusive if on 1-2 oral hypoglycemic agents

        Exclusion Criteria:

          1. Current insulin therapy

          2. Type 1 diabetes or secondary forms of diabetes

          3. Any major illness with a life expectancy of < 5 years or that may interfere with the
             patient's participation in the study

          4. Involvement in any other study requiring drug therapy

          5. Renal dysfunction as evidenced by serum creatinine >/= 136 umol/L for males or >/= 124
             umol/L for females or abnormal creatinine clearance (< 60 ml/min by Modification of
             Diet in Renal Disease (MDRD) formula)

          6. Hepatic disease considered to be clinically significant (includes jaundice, chronic
             hepatitis, or previous liver transplant) or transaminases > 2.5 times the upper limit
             of normal

          7. Excessive alcohol consumption, defined as > 14 alcoholic drinks per week for males and
             > 9 alcoholic drinks per week for females

          8. Pregnancy or unwillingness to use reliable contraception. Women should not be planning
             pregnancy for the duration of the study. Reliable contraception includes: birth
             control pill, intra-uterine device, abstinence, tubal ligation, partner vasectomy, or
             condoms with spermicide. Any women who miss a menstrual period or think that they may
             be pregnant must have a pregnancy test as soon as possible

          9. History of serious arrhythmia or atrioventricular block on baseline electrocardiogram

         10. Uncontrolled hypertension (systolic blood pressure > 180 mm Hg or diastolic blood
             pressure > 110 mm Hg)

         11. Unwillingness to undergo multiple daily insulin injection therapy for 4 weeks

         12. Unwillingness to perform capillary blood glucose monitoring at least 4 times per day
             during intensive insulin therapy
Clinical trial NCT00152477 (phase 2, status: completed)
Conditions: carcinoma, non-squamous non-small-cell lung cancer
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: carboplatin, paclitaxel, cdp791 10mg/kg, cdp791 20mg/kg
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female subjects with Stage IIIb (with malignant pleural effusion or if no
             pleural effusion is present subjects who are not candidates for combined modality
             therapy), Stage IV, or recurrent non-squamous, non-small-cell lung carcinoma.

          -  The subject must be aged 18 years or above.

          -  The subject must have ECOG performance status of 0 or 1 and a life expectancy of at
             least three months.

          -  Subjects will have measurable disease.

          -  The subject must be able to understand the information provided to them and to give
             written informed consent.

          -  Female subjects must be either postmenopausal, surgically sterilized, or using a
             method of contraception judged reliable by the Investigator.

          -  Male subjects must be using a method of contraception judged reliable by the
             Investigator.

        Exclusion Criteria:

          -  Subjects with squamous cell lung carcinoma.

          -  Subjects with lung lesions located centrally in the chest that involve major blood
             vessels.

          -  Concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ
             of the cervix. Subjects with previous malignancies are eligible provided that they
             have been disease free for five years or more.

          -  Presence of additional major chronic disease such as hepatic or renal dysfunction,
             cardiac dysfunction, peripheral vascular disease, evidence of a myocardial infarction
             within six months of Screening visit, tuberculosis or epilepsy.

          -  Subjects known to be infected with hepatitis B or C virus or HIV 1 or 2.

          -  Any evidence of serious active infection (ie requiring an iv antibiotic or antiviral
             agent).
Clinical trial NCT00005852 (phase 2, status: terminated)
Conditions: chronic myeloproliferative disorders, graft versus host disease, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes
ICD codes: D47.1, D89.810, D89.811, D89.813, D89.812, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C96.20, C96.29, D47.09, D46.9, D46.C, D46.Z
Drugs: cyclophosphamide, cyclosporine, methylprednisolone
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed aplastic anemia Must have related donor
        with a genotypic 6 out of 6 HLA A, B, and DR match OR Bone marrow transplant failure Must
        have related donor with at least a 5 out of 6 HLA match OR Must have an unrelated donor
        with at least a 5 out of 6 HLA match

        PATIENT CHARACTERISTICS: Age: 15 to 55 Performance status: Aplastic anemia patients:
        Karnofsky 80-100% Graft failure patients: Karnofsky 20-100% Life expectancy: Not specified
        Hematopoietic: See Disease Characteristics Hepatic: Aplastic anemia patients: Bilirubin no
        greater than 2.0 mg/dL SGOT/SGPT no greater than 3 times normal PT/PTT normal (except when
        aplastic anemia secondary to viral hepatitis) Graft failure patients: Mild to severe
        venoocclusive disease allowed Renal: Aplastic anemia patients: Creatinine no greater than
        2.0 mg/dL Creatinine clearance at least 60 mL/min Cardiovascular: Aplastic anemia patients:
        Left ventricular ejection fraction at least 45% by MUGA or echocardiography No myocardial
        infarction within the past 6 months No uncontrolled arrhythmias Pulmonary: Aplastic anemia
        patients: FEV1 and DLCO at least 50% predicted Other: Aplastic anemia patients: No
        uncontrolled diabetes mellitus or thyroid disease No active serious infections HIV negative
        Not pregnant or nursing Negative pregnancy test No psychosocial problem that would preclude
        study compliance

        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: Not
        specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not
        specified
Clinical trial NCT00502307 (phase 2, status: completed)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: tivozanib (av-951), placebo comparator
SMILES: COC1=C(OC)C=C2C(OC3=CC(Cl)=C(C=C3)N=C(O)N=C3NOC(C)=C3)=CC=NC2=C1, [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  ≥ 18 year old males or females

          -  Patients with recurrent or metastatic renal cell carcinoma (RCC) or primary RCC that
             is not amendable to surgical intervention

          -  Histologically or cytologically confirmed renal cell carcinoma

          -  Measurable disease

          -  No more than one prior systemic treatment (chemotherapy or immunotherapy) for RCC.

          -  No active brain metastases

          -  Karnofsky performance status ≥ 70%, life expectancy ≥ 3 months

          -  No childbearing potential, or use of effective contraception during the study and for
             4 weeks after the last dose of study drug

          -  Archival paraffin embedded tumor tissue, if available.

          -  Ability to give written informed consent

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Primary CNS malignancies; active CNS metastases

          -  Hematologic malignancies (includes: leukemia, any form; lymphoma; and multiple
             myeloma)

          -  Any of the following hematologic abnormalities:

               -  Hemoglobin ≤ 9.0 g/dL

               -  ANC < 1500 per mm3

               -  Platelet count < 100,000 per mm3

          -  Any of the following serum chemistry abnormalities:

               -  Total bilirubin > 1.5 × the ULN

               -  AST or ALT ≥ 2.5 × the ULN

               -  Serum albumin < 3.0 g/dL

               -  Creatinine > 1.7 × ULN (or calculated CLCR <50 mL/min/1.73 m2)

               -  Proteinuria > 2.5 g/24 hours or 4+ with urine dipstick

          -  Significant cardiovascular disease, including:

               -  Active clinically symptomatic left ventricular failure

               -  Active HTN (diastolic blood pressure > 100 mmHg). Patients with a history of
                  hypertension must have been on stable doses of anti-hypertensive drugs for ≥ 4
                  weeks

               -  Uncontrolled hypertension: Blood pressure >140/90 mmHg on more than 2
                  antihypertensive medications.

               -  Myocardial infarction within 3 months prior to administration of first study dose

          -  Unhealed wounds (including active gastric ulcers)

          -  Serious/active infection; infection requiring parenteral antibiotics

          -  Inadequate recovery from prior antineoplastic therapy

          -  Inadequate recovery from any prior surgical procedure; major surgical procedure within
             4 weeks prior to study entry

          -  Life-threatening illness or organ system dysfunction compromising safety evaluation

          -  Psychiatric disorder, altered mental status precluding informed consent or necessary
             testing

          -  Inability to comply with protocol requirements
Clinical trial NCT00671515 (phase 2, status: completed)
Conditions: depressive disorder, major, metabolic syndrome x
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40, E88.81, G93.41, E88.9, P19.9, E88.89, O21.1, P19.2
Drugs: pioglitazone
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Be male or female between the ages of 18 and 70

          -  DSM-IV diagnosis of major depressive disorder

          -  Currently depressed as confirmed by the MINI-Plus at the screening visit

          -  Quick Inventory of Depressive Symptomatology-Self-Report(QIDS-SR) score > 11 at study
             baseline

          -  Meets criteria for the metabolic syndrome as defined by the NCEP ATP III criteria

        Exclusion Criteria:

          -  Pregnancy or breast feeding

          -  Unstable or inadequately treated medical illness as judged by the investigator

          -  Severe personality disorder

          -  Serious suicidal risk as judged by the investigator or having a score > 2 on item 18
             of the Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR) scale

          -  Known history of intolerance or hypersensitivity to pioglitazone

          -  Treatment with pioglitazone in the 3 months prior to randomization

          -  Currently taking an antidiabetic/glucose-lowering agent. Antidiabetic agents that are
             prohibited include insulin, rosiglitazone, metformin, sitagliptin, sulfonylureas (e.g.
             glyburide, glipizide, glimepiride), non-sulfonylurea secretagogues (e.g. repaglinide,
             nateglinide), incretins (e.g. exenatide), and α-glucosidase inhibitors (e.g. acarbose,
             miglitol).

          -  Diagnosed with dementia

          -  Diagnosed with heart failure

          -  Transaminase elevation >2.5 times the upper limit of normal

          -  Presence of renal impairment
Clinical trial NCT00254787 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: ir (immediate-release) quetiapine fumarate (drug)
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women age ≥18 to ≤65 years with acute schizophrenia

          -  Provision of written informed consent prior to enrolment

        Exclusion Criteria:

          -  Meeting the criteria for any other (than schizophrenia) psychotic disorder not in full
             remission, concomitant organic mental disorder or mental retardation

          -  Patients with substance dependence

          -  Female patients who are pregnant, lactating or at risk of pregnancy
Clinical trial NCT00561951 (phase 2, status: completed)
Conditions: overactive bladder
ICD codes: N32.81
Drugs: fesoterodine fumarate, placebo, fesoterodine fumarate
SMILES: CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Adult OAB patients who present with OAB symptoms, including micturitions >= 8 per day
             and urgency urinary incontinence >= 1 per day.

        Exclusion Criteria:

          -  Patient has known hypersensitivity to the active substance (fesoterodine fumarate) or
             to peanut or soya or any of the excipients.

          -  Patient has a known neurological disease influencing bladder function.

          -  Patient has a complication of lower urinary tract pathology potentially responsible
             for urgency or incontinence, clinically relevant bladder outlet obstruction or pelvic
             organ prolapse.